Early researcher

Nuria Álvarez Pizarroso


I completed my Bachelor of Science (BSc) in Pharmacy at Francisco de Vitoria University (Madrid, Spain). I did internships both in the field of research and in the clinics. At the International Iberian Nanotechnology Lab (Braga, Portugal) I was able to investigate the nanoencapsulation of peptides. At the end of my stay, I had been able to develop encapsulated satiating peptide nanoparticles, which were released specifically in the duodenum and induced the release of satiating hormones. This novel formulation is positioned as a promising strategy to induce satiety in patients with obesity problems. From this work, I was able to write both my master's thesis and two articles which are currently published. 

See more

On the other hand, I had the opportunity to do an internship in the Pharmacy Department of the Hospital de El Escorial (Madrid, Spain), where I was able to obtain valuable knowledge about pharmacological  guidelines, the preparation of parenteral drugs and nutrition, personalized studies of dose- response, adverse effects and medication reconciliation. At the beginning of 2023, I moved to Paris to start working on the investigation of the migration dynamics of the different cell populations of the immune system. For a few months, I investigated actin dynamics in populations such as neutrophils, dendritic cells, and T lymphocytes, in addition to gaining valuable knowledge on microscopy tools.

See less


Since I did my internship in the field of research, it was clear to me that my passion was research. I discovered that my motivation was mainly in the field of translational research. That is why I am currently dedicated to studying haematological malignancies, specifically Acute Myeloid Leukaemia (AML).

During the next few years my goal is to analyse and identify different mutations in IDH-1 and IDH-2 in samples from relapse AML patients. In addition, I will identify at the single cell level the gene expression signatures associated with resistance to IDH inhibitor as monotherapy or combination with transcriptomic, proteomic and epigenomic approaches. The purpose is to identify in vitro and then validate in vivo therapeutic combinations reverting the expression of resistance signatures to IDH inhibitors.